The  ||| S:0 E:4 ||| DT
management  ||| S:4 E:15 ||| NN
of  ||| S:15 E:18 ||| IN
iron  ||| S:18 E:23 ||| NN
deficiency  ||| S:23 E:34 ||| NN
in  ||| S:34 E:37 ||| IN
menometrorrhagia  ||| S:37 E:54 ||| JJ
Iron-deficiency  ||| S:54 E:70 ||| JJ
anaemia ||| S:70 E:77 ||| NN
,  ||| S:77 E:79 ||| ,
the  ||| S:79 E:83 ||| DT
condition  ||| S:83 E:93 ||| NN
in  ||| S:93 E:96 ||| IN
which  ||| S:96 E:102 ||| WDT
anaemia  ||| S:102 E:110 ||| RB
occurs  ||| S:110 E:117 ||| VBZ
due  ||| S:117 E:121 ||| JJ
to  ||| S:121 E:124 ||| TO
a  ||| S:124 E:126 ||| DT
lack  ||| S:126 E:131 ||| NN
of  ||| S:131 E:134 ||| IN
iron ||| S:134 E:138 ||| NN
,  ||| S:138 E:140 ||| ,
develops  ||| S:140 E:149 ||| VBZ
when  ||| S:149 E:154 ||| WRB
the  ||| S:154 E:158 ||| DT
amount  ||| S:158 E:165 ||| NN
of  ||| S:165 E:168 ||| IN
available  ||| S:168 E:178 ||| JJ
iron  ||| S:178 E:183 ||| NN
is  ||| S:183 E:186 ||| VBZ
insufficient  ||| S:186 E:199 ||| JJ
to  ||| S:199 E:202 ||| TO
support  ||| S:202 E:210 ||| VB
normal  ||| S:210 E:217 ||| JJ
red  ||| S:217 E:221 ||| JJ
blood  ||| S:221 E:227 ||| NN
cell  ||| S:227 E:232 ||| NN
production ||| S:232 E:242 ||| NN
.  ||| S:242 E:244 ||| .
Iron  ||| S:244 E:249 ||| NNP
deficiency  ||| S:249 E:260 ||| NN
and  ||| S:260 E:264 ||| CC
iron-deficiency  ||| S:264 E:280 ||| JJ
anaemia ||| S:280 E:287 ||| NN
,  ||| S:287 E:289 ||| ,
very  ||| S:289 E:294 ||| RB
prevalent  ||| S:294 E:304 ||| JJ
conditions  ||| S:304 E:315 ||| NNS
in  ||| S:315 E:318 ||| IN
premenopausal  ||| S:318 E:332 ||| JJ
women ||| S:332 E:337 ||| NNS
,  ||| S:337 E:339 ||| ,
are  ||| S:339 E:343 ||| VBP
often  ||| S:343 E:349 ||| RB
associated  ||| S:349 E:360 ||| VBN
with  ||| S:360 E:365 ||| IN
menometrorrhagia  ||| S:365 E:382 ||| NNS
( ||| S:382 E:383 ||| -LRB-
present  ||| S:383 E:391 ||| JJ
in  ||| S:391 E:394 ||| IN
more  ||| S:394 E:399 ||| JJR
than  ||| S:399 E:404 ||| IN
two-thirds  ||| S:404 E:415 ||| NNS
of  ||| S:415 E:418 ||| IN
cases  ||| S:418 E:424 ||| NNS
of  ||| S:424 E:427 ||| IN
iron-deficiency  ||| S:427 E:443 ||| JJ
anaemia  ||| S:443 E:451 ||| NN
in  ||| S:451 E:454 ||| IN
premenopausal  ||| S:454 E:468 ||| JJ
women ||| S:468 E:473 ||| NNS
) ||| S:473 E:474 ||| -RRB-
.  ||| S:474 E:476 ||| .
Appropriate  ||| S:476 E:488 ||| JJ
identification  ||| S:488 E:503 ||| NN
and  ||| S:503 E:507 ||| CC
treatment  ||| S:507 E:517 ||| NN
of  ||| S:517 E:520 ||| IN
iron  ||| S:520 E:525 ||| NN
deficiency  ||| S:525 E:536 ||| NN
is  ||| S:536 E:539 ||| VBZ
imperative  ||| S:539 E:550 ||| VBN
as  ||| S:550 E:553 ||| IN
iron  ||| S:553 E:558 ||| NN
deficiency  ||| S:558 E:569 ||| NN
can  ||| S:569 E:573 ||| MD
induce  ||| S:573 E:580 ||| VB
important  ||| S:580 E:590 ||| JJ
specific  ||| S:590 E:599 ||| JJ
clinical  ||| S:599 E:608 ||| JJ
manifestations  ||| S:608 E:623 ||| NNS
( ||| S:623 E:624 ||| -LRB-
including  ||| S:624 E:634 ||| VBG
fatigue ||| S:634 E:641 ||| NN
,  ||| S:641 E:643 ||| ,
atrophic  ||| S:643 E:652 ||| JJ
changes  ||| S:652 E:660 ||| NNS
in  ||| S:660 E:663 ||| IN
the  ||| S:663 E:667 ||| DT
epithelium ||| S:667 E:677 ||| NN
,  ||| S:677 E:679 ||| ,
oral  ||| S:679 E:684 ||| JJ
lesions ||| S:684 E:691 ||| NNS
,  ||| S:691 E:693 ||| ,
dysphagia ||| S:693 E:702 ||| NN
,  ||| S:702 E:704 ||| ,
nail  ||| S:704 E:709 ||| JJ
lesions ||| S:709 E:716 ||| NNS
,  ||| S:716 E:718 ||| ,
reduced  ||| S:718 E:726 ||| VBD
immune  ||| S:726 E:733 ||| JJ
response ||| S:733 E:741 ||| NN
) ||| S:741 E:742 ||| -RRB-
.  ||| S:742 E:744 ||| .
Iron  ||| S:744 E:749 ||| NNP
supplementation  ||| S:749 E:765 ||| NN
is  ||| S:765 E:768 ||| VBZ
the  ||| S:768 E:772 ||| DT
most  ||| S:772 E:777 ||| RBS
common  ||| S:777 E:784 ||| JJ
strategy  ||| S:784 E:793 ||| NN
used  ||| S:793 E:798 ||| VBN
to  ||| S:798 E:801 ||| TO
control  ||| S:801 E:809 ||| VB
iron  ||| S:809 E:814 ||| NN
deficiency ||| S:814 E:824 ||| NN
.  ||| S:824 E:826 ||| .
Based  ||| S:826 E:832 ||| VBN
on  ||| S:832 E:835 ||| IN
World  ||| S:835 E:841 ||| NNP
Health  ||| S:841 E:848 ||| NNP
Organisation  ||| S:848 E:861 ||| NNP
recommendations ||| S:861 E:876 ||| NNS
,  ||| S:876 E:878 ||| ,
the  ||| S:878 E:882 ||| DT
most  ||| S:882 E:887 ||| RBS
appropriate  ||| S:887 E:899 ||| JJ
treatment  ||| S:899 E:909 ||| NN
is  ||| S:909 E:912 ||| VBZ
with  ||| S:912 E:917 ||| IN
an  ||| S:917 E:920 ||| DT
oral  ||| S:920 E:925 ||| JJ
ferrous  ||| S:925 E:933 ||| JJ
salt  ||| S:933 E:938 ||| NN
in  ||| S:938 E:941 ||| IN
a  ||| S:941 E:943 ||| DT
prolonged-release  ||| S:943 E:961 ||| JJ
tablet  ||| S:961 E:968 ||| JJ
form ||| S:968 E:972 ||| NN
,  ||| S:972 E:974 ||| ,
to  ||| S:974 E:977 ||| TO
provide  ||| S:977 E:985 ||| VB
a  ||| S:985 E:987 ||| DT
dose  ||| S:987 E:992 ||| NN
of  ||| S:992 E:995 ||| IN
elemental  ||| S:995 E:1005 ||| JJ
iron  ||| S:1005 E:1010 ||| NN
equivalent  ||| S:1010 E:1021 ||| NN
to  ||| S:1021 E:1024 ||| TO
60  ||| S:1024 E:1027 ||| CD
mg  ||| S:1027 E:1030 ||| NN
per  ||| S:1030 E:1034 ||| IN
intake ||| S:1034 E:1040 ||| NN
,  ||| S:1040 E:1042 ||| ,
in  ||| S:1042 E:1045 ||| IN
the  ||| S:1045 E:1049 ||| DT
range  ||| S:1049 E:1055 ||| NN
of  ||| S:1055 E:1058 ||| IN
60  ||| S:1058 E:1061 ||| CD
and  ||| S:1061 E:1065 ||| CC
120  ||| S:1065 E:1069 ||| CD
mg ||| S:1069 E:1071 ||| CD
/ ||| S:1071 E:1072 ||| CD
day  ||| S:1072 E:1076 ||| NN
according  ||| S:1076 E:1086 ||| VBG
to  ||| S:1086 E:1089 ||| TO
the  ||| S:1089 E:1093 ||| DT
severity  ||| S:1093 E:1102 ||| NN
of  ||| S:1102 E:1105 ||| IN
iron-deficiency  ||| S:1105 E:1121 ||| JJ
anaemia ||| S:1121 E:1128 ||| NN
.  ||| S:1128 E:1130 ||| .
When  ||| S:1130 E:1135 ||| WRB
haemoglobin  ||| S:1135 E:1147 ||| JJ
levels  ||| S:1147 E:1154 ||| NNS
have  ||| S:1154 E:1159 ||| VBP
returned  ||| S:1159 E:1168 ||| VBN
to  ||| S:1168 E:1171 ||| TO
normal ||| S:1171 E:1177 ||| JJ
,  ||| S:1177 E:1179 ||| ,
treatment  ||| S:1179 E:1189 ||| NN
should  ||| S:1189 E:1196 ||| MD
continue  ||| S:1196 E:1205 ||| VB
for  ||| S:1205 E:1209 ||| IN
about  ||| S:1209 E:1215 ||| IN
3  ||| S:1215 E:1217 ||| CD
months  ||| S:1217 E:1224 ||| NNS
to  ||| S:1224 E:1227 ||| TO
fill  ||| S:1227 E:1232 ||| VB
iron  ||| S:1232 E:1237 ||| NN
stores ||| S:1237 E:1243 ||| NNS
.  ||| S:1243 E:1245 ||| .
An  ||| S:1245 E:1248 ||| DT
extended-release  ||| S:1248 E:1265 ||| JJ
formulation  ||| S:1265 E:1277 ||| NN
of  ||| S:1277 E:1280 ||| IN
ferrous  ||| S:1280 E:1288 ||| JJ
sulphate  ||| S:1288 E:1297 ||| NN
with  ||| S:1297 E:1302 ||| IN
mucoproteose  ||| S:1302 E:1315 ||| NN
has  ||| S:1315 E:1319 ||| VBZ
been  ||| S:1319 E:1324 ||| VBN
shown  ||| S:1324 E:1330 ||| VBN
to  ||| S:1330 E:1333 ||| TO
be  ||| S:1333 E:1336 ||| VB
associated  ||| S:1336 E:1347 ||| VBN
with  ||| S:1347 E:1352 ||| IN
a  ||| S:1352 E:1354 ||| DT
lower  ||| S:1354 E:1360 ||| JJR
incidence  ||| S:1360 E:1370 ||| NN
of  ||| S:1370 E:1373 ||| IN
gastrointestinal  ||| S:1373 E:1390 ||| JJ
adverse  ||| S:1390 E:1398 ||| JJ
effects  ||| S:1398 E:1406 ||| NNS
compared  ||| S:1406 E:1415 ||| VBN
with  ||| S:1415 E:1420 ||| IN
other  ||| S:1420 E:1426 ||| JJ
ferrous  ||| S:1426 E:1434 ||| NN
and  ||| S:1434 E:1438 ||| CC
ferric  ||| S:1438 E:1445 ||| JJ
salts ||| S:1445 E:1450 ||| NN
.  ||| S:1450 E:1452 ||| .
